PANSS

Published research on PANSS.

DrugsJul 4, 2026

Cholinergic Modulators Improved Schizophrenia Negative Symptoms

A 30-trial meta-analysis found that cholinergic modulators improved schizophrenia negative symptoms, SMD −0.42, while the overall total PANSS/BPRS effect was not statistically significant.1 …

Read article →

DrugsJul 2, 2026

Antipsychotic Dose Was Not Linked to MoCA in Schizophrenia

A 2026 cross-sectional schizophrenia study found no meaningful association between antipsychotic dose and Montreal Cognitive Assessment (MoCA) performance in young, clinically stable outpati…

Read article →

DrugsMay 20, 2026

PDE10A Inhibitor MK-8189 Fails Phase 2b Schizophrenia Trial

Mukai et al.’s 499-person Phase 2b schizophrenia trial tested whether higher, sustained PDE10A inhibition could turn MK-8189 into a non-D2 antipsychotic; it did not. At week 6, MK-8189 misse…

Read article →

DrugsMay 3, 2026

Lurasidone Improves Positive Symptoms of Schizophrenia More Than Negative

Lurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysi…

Read article →

PsychologyMay 3, 2026

Black Americans Diagnosed with Schizophrenia 2.42x the Rate of White Americans: More Negative Symptoms

Black Americans are diagnosed with schizophrenia-spectrum disorders at 2.42 times the rate of White Americans, and they also score higher on negative-symptom measures than White patients car…

Read article →